Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Delayed Nasdaq Other stock markets 04:00:00 2026-01-16 pm EST			5-day change	1st Jan Change
330.41 ^USD	+0.12%		+1.32%	+0.95%

Jan. 15	Espiria Hållbar Framtid Rises 0.4 Percent in December — Increased Holdings in Epiroc and Afry	FW
Jan. 14	Honeywell Says Quantinuum Plans Confidential Filing of IPO Draft Registration	MT

Weight-loss drug developers line up to tap lucrative market as competition heats up

Published on 11/25/2025 at 08:41 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Amgen Inc.

Jan. 15	Espiria Hållbar Framtid Rises 0.4 Percent in December — Increased Holdings in Epiroc and Afry	FW
Jan. 14	Honeywell Says Quantinuum Plans Confidential Filing of IPO Draft Registration	MT
Jan. 13	Ro partners with Amgen to study barriers to obesity care, GLP-1 access	RE
Jan. 13	Ro partners with Amgen to study barriers to obesity care, GLP-1 access	RE
Jan. 13	Analyst recommendations: JPMorgan, Meta, Citigroup, BlackRock, AbbVie…
Jan. 13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI
Jan. 13	Alert incorrectly tagged to Rubicon Organics withdrawn	RE
Jan. 13	The CPI That Changed Almost Nothing
Jan. 13	Ro announces research collaboration with Amgen to evaluate real-world GLP-1 coverage	RE
Jan. 13	Global drugmakers rush to boost US presence as tariff threat looms	RE
Jan. 13	Amgen's Extension Study Shows MariTide Helped Maintain Weight Loss at Lower Dose, Less Frequency	MT
Jan. 13	Focus on inflation and corporate earnings
Jan. 12	Amgen Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 03:45 PM
Jan. 12	Amgen says MariTide helped trial patients maintain weight loss	RE
Jan. 12	Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight	RE
Jan. 12	Amgen: Second year of Maritide treatment very well tolerated including at quarterly doses, with very low incidence of nausea, vomiting & no new safety signals observed	RE
Jan. 12	Amgen: "Large majority" of people in 52-week Maritide extension study given lower monthly dose or quarterly dose of drug maintained weight loss achieved in part 1 of phase 2 trial	RE
Jan. 12	Amgen says 24-week study of monthly Maritide in people with type 2 diabetes showed robust, clinically meaningful reduction in both HbA1c, weight	RE
Jan. 12	Amgen to announce data on obesity drug MariTide at healthcare conference	RE
Jan. 12	BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer	MT
Jan. 12	BioMarin Pharmaceutical Inc. Appoints Arpit Davé as Executive Vice President and Chief Digital and Information Officer	CI
Jan. 12	Spyre Therapeutics, Inc. Appoints Kate Tansey Chevlen as Chief Commercial Officer	CI
Jan. 12	Zymeworks Inc. Announces Management Changes	CI
Jan. 08	Praxis Precision Medicines, Inc. Announces Management Changes	CI
Jan. 08	Goldman Sachs Adjusts Price Target on Amgen to $403 From $400, Maintains Buy Rating	MT

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.4% of net sales.

Employees

28,000

Sector

Pharmaceuticals

Calendar

Feb. 03 - Q4 2025 Earnings Release

More about the company